LifeMD, Inc.— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q1+Q2+Q3+Q4) vs FY2024 (Q1+Q2+Q3+Q4)
Revenue
$194M
↓-6.5% -$14Mvs FY2024 (Q1+Q2+Q3+Q4)
Gross Profit
$166M
↓-10.5% -$20Mvs FY2024 (Q1+Q2+Q3+Q4)
Operating profit
$165M
↓-10.7% -$20Mvs FY2024 (Q1+Q2+Q3+Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q1+Q2+Q3+Q4) | FY2024 (Q1+Q2+Q3+Q4) |
|---|---|---|
| Revenue | $194M | $208M |
| COGS | $28M | $22M |
| Gross Profit | $166M | $186M |
| R&D | $0 | $0 |
| SG&A | $0 | $0 |
| D&A | $866K | $466K |
| Other OpEx | $0 | $0 |
| Operating Income | $165M | $185M |
| Interest Exp. | $2M | $2M |
| Other Non-Op | $164M | $163M |
| Pretax Income | $0 | $20M |
| Tax | $0 | $20M |
| Net Income | $0 | $0 |
QuarterCharts · SEC EDGAR data · LFMD · Comparing FY2025 (Q1+Q2+Q3+Q4) vs FY2024 (Q1+Q2+Q3+Q4)